Helixmith Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ji-Wook Jeong

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans

Oct 18

Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?

Feb 19

AMMINISTRATORE DELEGATO

Ji-Wook Jeong

less than a year

Mandato

Ji-Wook Jeong is CEO & President of Helixmith Co. Ltd from 2024.

Helixmith Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

No independent directors

No independent directors

Recent updates

New minor risk - Market cap size

Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans

Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding

New minor risk - Share price stability

Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc.

Price target decreased to ₩19,900

No independent directors

Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD)

Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)

Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19

First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021)

Price target increased to ₩29,182

Price target decreased to ₩26,529

No independent directors

Price target decreased to ₩26,529

Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS

Price target decreased to ₩33,000

New 90-day low: ₩24,550

Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today?

Wacker Chemie AG (XTRA:WCH) entered into an agreement to acquire Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd (KOSDAQ:A084990) for $39 million.

Helixmith Co., Ltd announced that it has received KRW 20 billion in funding

Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in funding

Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion.

New 90-day low: ₩30,750

Helixmith to Be Deleted from Other OTC

New 90-day low: ₩41,800

New 90-day low - ₩52,000

New 90-day low - ₩56,500

AMMINISTRATORE DELEGATO

Mandato